KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Expenses (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Operating Expenses data on record, last reported at $266.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 151.27% year-over-year to $266.6 million; the TTM value through Dec 2025 reached $966.7 million, up 32.97%, while the annual FY2025 figure was $966.7 million, 32.97% up from the prior year.
  • Operating Expenses reached $266.6 million in Q4 2025 per ACAD's latest filing, up from $242.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $269.5 million in Q3 2023 and bottomed at $106.1 million in Q4 2024.
  • Average Operating Expenses over 5 years is $194.4 million, with a median of $186.6 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: tumbled 45.89% in 2024, then skyrocketed 151.27% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $175.4 million in 2021, then rose by 4.07% to $182.6 million in 2022, then grew by 7.42% to $196.1 million in 2023, then crashed by 45.89% to $106.1 million in 2024, then surged by 151.27% to $266.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $266.6 million in Q4 2025, $242.9 million in Q3 2025, and $232.2 million in Q2 2025.